Anagenics Ltd
ASX:AN1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Anagenics Ltd
Income from Continuing Operations
Anagenics Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Anagenics Ltd
ASX:AN1
|
Income from Continuing Operations
-AU$1.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Holista CollTech Ltd
ASX:HCT
|
Income from Continuing Operations
-AU$951.4k
|
CAGR 3-Years
14%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Bioxyne Ltd
ASX:BXN
|
Income from Continuing Operations
AU$8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
37%
|
|
|
McPherson's Ltd
ASX:MCP
|
Income from Continuing Operations
-AU$17.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Star Combo Pharma Ltd
ASX:S66
|
Income from Continuing Operations
AU$5.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
B
|
Biome Australia Ltd
ASX:BIO
|
Income from Continuing Operations
AU$214.7k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Anagenics Ltd
Glance View
Anagenics Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The principal activities of the Company include the development, distribution and sale of health, beauty and wellness products (Consumer health). The firm through its wholly owned subsidiary Advangen Pty Ltd, develops, manufactures, markets, distributes to retailers, and sells its anti-aging products globally, with its FGF5 inhibitor, hair health and hair growth products. The flagship anti-aging hair care range, marketed as evolis, Advangen Jo-Ju, and Lexilis brands are sold in Australia, Japan, and the United States of America. The Company’s subsidiary is BLC Cosmetics Pty Limited, which is the distributor of premium Australian and international beauty and wellness brands, primarily to salons and spas.
See Also
What is Anagenics Ltd's Income from Continuing Operations?
Income from Continuing Operations
-1.2m
AUD
Based on the financial report for Jun 30, 2025, Anagenics Ltd's Income from Continuing Operations amounts to -1.2m AUD.
What is Anagenics Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
22%
Over the last year, the Income from Continuing Operations growth was 83%. The average annual Income from Continuing Operations growth rates for Anagenics Ltd have been 9% over the past three years , 22% over the past five years .
